Research Analysts Offer Predictions for ITOS Q1 Earnings

iTeos Therapeutics, Inc. (NASDAQ:ITOS) – Investment analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a research report issued on Wednesday, March 5th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($0.68) per share for the quarter, up from their prior forecast of ($0.79). Wedbush has a “Outperform” rating and a $25.00 price objective on the stock. The consensus estimate for iTeos Therapeutics’ current full-year earnings is ($3.49) per share. Wedbush also issued estimates for iTeos Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.77) EPS, Q4 2025 earnings at ($0.83) EPS, FY2025 earnings at ($3.09) EPS, FY2026 earnings at ($3.95) EPS, FY2027 earnings at ($4.63) EPS and FY2028 earnings at ($4.32) EPS.

Several other equities research analysts have also recently weighed in on the company. JPMorgan Chase & Co. dropped their price objective on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday. Wells Fargo & Company dropped their price target on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $46.00 price objective on shares of iTeos Therapeutics in a research report on Thursday.

iTeos Therapeutics Trading Down 0.6 %

iTeos Therapeutics stock opened at $7.05 on Monday. The firm has a market cap of $257.56 million, a P/E ratio of -2.24 and a beta of 1.38. iTeos Therapeutics has a 1-year low of $6.67 and a 1-year high of $18.75. The firm has a 50-day moving average of $7.52 and a 200-day moving average of $9.36.

iTeos Therapeutics (NASDAQ:ITOS) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Creative Planning increased its stake in shares of iTeos Therapeutics by 6.5% during the third quarter. Creative Planning now owns 19,636 shares of the company’s stock valued at $200,000 after purchasing an additional 1,196 shares in the last quarter. US Bancorp DE grew its stake in shares of iTeos Therapeutics by 206.0% in the 3rd quarter. US Bancorp DE now owns 12,076 shares of the company’s stock worth $123,000 after buying an additional 8,129 shares during the last quarter. GSA Capital Partners LLP bought a new position in iTeos Therapeutics during the 3rd quarter valued at approximately $263,000. Empowered Funds LLC raised its stake in iTeos Therapeutics by 5.4% during the third quarter. Empowered Funds LLC now owns 65,767 shares of the company’s stock valued at $671,000 after buying an additional 3,350 shares during the last quarter. Finally, Quest Partners LLC boosted its holdings in iTeos Therapeutics by 914.7% in the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after acquiring an additional 9,934 shares in the last quarter. 97.16% of the stock is owned by hedge funds and other institutional investors.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.